Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Early Aortic Aneurism Stent Repairs Carries Risk

By HospiMedica staff writers
Posted on 02 Feb 2007
A new study has found that first-generation stent grafts used for endovascular repair of abdominal aortic aneurysms (EVARs) have been associated with high rates of late failures, often leading to death.

Researchers at the European Cobalt Chromium Stent with Antiproliferative for Restenosis Trial (EUROSTAR) data registry center at Catharina Hospital (Eindhoven, The Netherlands) prospectively collected results of EVARs performed on 1,180 patients in Europe between 1994 and 1999 who were followed for up to eight years. More...
Aneurysm diameters were small (between 40 mm and 54 mm) in 581 patients, and 55 mm or larger in 609. Larger aneurysms tended to be associated with older age, diabetes, and diseases of the heart, carotid artery, and lungs, and experienced complications at about twice the rate of those with smaller defects.

First-month mortality was 2.9%, and systemic complications occurred in 12.9% of the patients during their hospitalization. Cumulative survival after eight years was 74.5% among patients with small aneurysms and 49.6% in the remaining subjects. Procedure-related complications observed included endoleak (13 cases per 100 patient-years), stenosis/thrombosis (4.6 cases per 100 patient-years), and stent migration (4.3 cases per 100 patient-years). Structural failure of the stents included fabric tears, fractures caused by metal fatigue, breakdown of polypropylene sutures, and insufficient fixation. The findings were reported in the January 2007 edition of the Archives of Surgery.

"Patients treated with the first generation of stent grafts will need lifelong surveillance because of a considerable risk of late complications,” concluded lead author Dr. Lina J. Leurs and colleagues of EUROSTAR. "For this reason, vigilant surveillance remains indicated in all patients who undergo endovascular abdominal aortic aneurysm repair.”

The devices reviewed were the Stentor, previously manufactured by MinTec (La Ciotat, France), now a part of Boston Scientific, and the Vanguard, an early product of Boston Scientific (Natick, MA, USA).



Related Links:
Catharina Hospital
Boston Scientific

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.